Can Abbott Laboratories Beat Baxter International and Edwards Lifesciences in 2014?

After a tough 2013 for Abbott Laboratories (NYSE: ABT), can it beat sector peers Baxter International and Edwards Lifesciences in 2014?

Feb 26, 2014 at 4:31PM

The year 2013 proved to be a rather frustrating one for shareholders in Abbott Laboratories (NYSE:ABT). Indeed, shares were outperformed by the S&P 500, with the index delivering capital gains of 32% while Abbott Laboratories managed only 19%.

However, Abbott Laboratories was not the only Healthcare Equipment stock to be handsomely beaten by the S&P 500. Sector peers Baxter International (NYSE:BAX) and Edwards Lifesciences (NYSE:EW) fared worse than Abbott Laboratories in 2013, posting returns of 6% and -26%, respectively.

This trend has, encouragingly, not continued thus far in 2014, with Edwards Lifesciences and Abbott Laboratories ahead of the index in 2014 (+3.2% and +2.4%, respectively), while Baxter International is down 1.3% -- just behind the S&P 500's return of -0.2% year to date. Can Abbott Laboratories beat its two main rivals (and the index) in 2014?

An unfair 2013?
It's often said that the stock market looks beyond the current year's earnings. However, for Abbott Laboratories in 2013, this was certainly not the case. Earnings per share (EPS) in 2013 were around 46% lower than they were in 2012, but don't be fooled - this drop was actually due to Abbott spinning out its pharmaceutical division into AbbVie at the start of 2013. However, adjusting for this spinoff, Abbott's sales for the year came in slightly below expectations and earnings were in line with analyst estimates; these weren't the kind of results that generally gets investors excited about a stock.

Despite this, forecasts for 2014 and 2015 remain very upbeat, with Abbott Laboratories expected to deliver EPS growth of 9% in 2014, and 12% in 2015. Both of these numbers are well ahead of the average growth rate for S&P 500 stocks in 2014 and 2015, showing that Abbott Laboratories could still offer potential upside.

A tough 2013 for the sector
Indeed, it appears as though the market was focused on 2013 for Baxter International, too, as shares had a tough year. However, as with Abbott Laboratories, upside potential remains, because Baxter International is forecast to increase EPS by 10% in 2014, and by 6% in 2015, which does not yet appear to be fully reflected in the company's share price.

Meanwhile, Edwards Lifesciences saw profit in the fourth quarter fall by 17% versus the fourth quarter of 2012 as a result of higher selling and administrative expenses, as well as a charge related to severance expenses. In addition, EPS forecasts appear to be mixed for Edwards Lifesciences, with EPS forecast to drop by 4% in 2014 before rising by 16% in 2015, thereby giving an annualized rate of 5.5% in 2014 and 2015.

Looking Ahead
Although 2013 was a disappointing year for shareholders of Abbott Laboratories, with it underperforming the S&P 500, the future looks bright due to strong growth forecasts in 2014 and 2015. The same can be said for Baxter International, with strong growth expected to be delivered in 2014 and 2015 after a challenging 2013. Edwards Lifesciences, meanwhile, may struggle to keep pace with its two sector peers due to its lower expected EPS growth rate and dampened market sentiment after its tough fourth quarter.

As for whether Abbott Laboratories can beat Baxter International in 2014, its higher EPS growth rate in 2014 and 2015 (combined) give it a good chance, although there seems to be little to choose between the two stocks. However, both look set to have a strong 2014, and have a good chance of reversing their underperformance of the S&P 500 in 2013.

Another top growth stock for 2014
It's not just Abbott Laboratories that stands out as a top growth stock in 2014. Furthermore, there's a huge difference between a good stock and a stock that can make you rich. The Motley Fool's chief investment officer has selected his No. 1 stock for 2014, and it's one of those stocks that could make you rich. You can find out which stock it is in the special free report, "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.

Editor's Note: A previous version of this article incorrectly stated that Abbott Laboratories' EPS dropped 46% year over year and did not take the spinoff of Abbott's pharmaceutical division into account. The article has been updated and the Fool regrets the error.

Peter Stephens has no position in any stocks mentioned. The Motley Fool recommends Baxter International. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.

Compare Brokers